U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma With Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
Clinical Cancer Research- United States
doi 10.1158/1078-0432.ccr-07-1354
Full Text
Abstract
Available in
Date
March 1, 2008
Authors
Publisher
American Association for Cancer Research (AACR)